NTRK2 and obesity disorder: To evaluate the therapeutic potential of activating TrkB in vivo and to understand better the species differences and mechanisms behind them, we have generated a fully humanized TrkB agonist antibody, TAM-163, and tested its efficacy in several preclinical species and in different models of obesity.